Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kodiak Sciences soared by 74.77 percent on Thursday to finish at $39.76 apiece, as investors took heart from the strong results of its clinical study for its diabetic retinopathy treatment. In an updated report, Kodiak Sciences Inc. (NASDAQ:KOD) said that 62.5 percent of the enrolled patients in the GLOW clinical trial achieved a more than 2-step improvement in diabetic retinopathy severity score for those who took Zenkuda, as compared with 3.3 percent of the sham group. Photo by Nataliya Vaitkevich on Pexels The patients were randomized to receive either a sham injection or Zenkuda via intravitreal injection at progressively extended intervals. Zenkuda also showed an 85-percent risk reduction in sight-threatening complications. The drug candidate also demonstrated favorable safety and was well tolerated in the study, with a 0 percent intraocular inflammation rate and a 2.3 percent cataract adverse event rate, versus 1.6 percent with sham. "We are very pleased to see that G
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]Seeking Alpha
- Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.MarketBeat
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamPR Newswire
KOD
Earnings
- 11/13/25 - Miss
KOD
Sec Filings
- 3/27/26 - Form 4
- 3/27/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- KOD's page on the SEC website